Loading...
Aurinia Pharmaceuticals saw a robust quarter driven by LUPKYNIS sales, leading to a net income of $23.3M and positive operating cash flow.
LUPKYNIS net product sales reached $59.97M, up from $48.07M YoY.
Total revenue increased to $62.47M from $50.3M in Q1 2024.
Net income improved significantly to $23.34M from a net loss of $10.75M in Q1 2024.
Operating cash flow was $1.3M, or $12.4M excluding restructuring costs.
Aurinia reaffirmed its 2025 guidance for revenue and product sales, anticipating continued LUPKYNIS momentum.
Analyze how earnings announcements historically affect stock price performance